In addition, CALD1, TGFB3 and ANXA6 were identified as immune hub genes (MM > 0.85), which may serve as biomarkers for predicting the outcomes of patients with BLCA and selecting eligible patients for mRNA vaccination. This evidence concerns the gene CALD1 and bladder transitional cell carcinoma.